Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge

Group 1 - Amgen reported strong Q4 2025 results and provided full-year 2026 guidance that exceeded Street expectations [2] - The company is effectively managing losses of exclusivity on several large products [2] Group 2 - The Growth Stock Forum focuses on identifying attractive risk/reward situations in growth and biotech stocks [2]